SCHEMBL25933711

SCHEMBL25933711

CCC(C)(C)CCCNc1ncc(C(=O)O)cc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 4/20 0.40
ALDH1A1 P00352 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
STK17B O94768 1/20 0.37
STK17A Q9UEE5 1/20 0.37
POLB P06746 1/20 0.36
HDAC3 O15379 2/20 0.36
EPHX2 P34913 1/20 0.34
NR1H4 Q96RI1 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
KDM4E B2RXH2 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
RAB9A P51151 1/20 0.34
MEN1 O00255 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34
TP53 P04637 1/20 0.34
CYP3A4 P08684 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25933680 0.82 HCAR3 (0.54) HCAR3ALDH1A1L3MBTL1POLBHDAC3
SCHEMBL24214176 0.78 ALDH1A1 (0.46) ALDH1A1L3MBTL1POLBSMN1; SMN2GAA
SCHEMBL2421299 0.77 ALDH1A1 (0.41) HCAR3ALDH1A1POLBRAB9AMEN1
SCHEMBL3826302 0.75 STK17B (0.54) ALDH1A1STK17BSTK17APOLBGAA
SCHEMBL24214066 0.71 HCAR3 (0.40) HCAR3ALDH1A1L3MBTL1
SCHEMBL24100544 0.70 HCAR3 (0.57) HCAR3ALDH1A1L3MBTL1POLBHDAC3
SCHEMBL31132753 0.69 ALDH1A1 (0.47) HCAR3ALDH1A1POLBKDM4EGAA
SCHEMBL476528 0.69 ALDH1A1 (0.47) HCAR3ALDH1A1POLBKDM4EGAA
SCHEMBL9648858 0.68 ALDH1A1 (0.43) HCAR3ALDH1A1L3MBTL1POLBSMN1; SMN2
SCHEMBL6606946 0.68 ALDH1A1 (0.41) HCAR3ALDH1A1POLBSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250106-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250106-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 HCAR3 2347/4885ALDH1A1 4654/4885L3MBTL1 2331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.